Compare BHR & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | ANIX |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.2M | 114.0M |
| IPO Year | 2013 | 2013 |
| Metric | BHR | ANIX |
|---|---|---|
| Price | $1.94 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 326.9K | 238.5K |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $487,614,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.83 | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.88 | $2.32 |
| 52 Week High | $3.19 | $5.46 |
| Indicator | BHR | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.28 | 37.85 |
| Support Level | $1.88 | $2.77 |
| Resistance Level | $2.63 | $3.53 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 4.88 | 0.00 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.